Next Article in Journal
Highly Efficient and Heritable Targeted Mutagenesis in Wheat via the Agrobacterium tumefaciens-Mediated CRISPR/Cas9 System
Next Article in Special Issue
The Molecular Chaperone DNAJB6, but Not DNAJB1, Suppresses the Seeded Aggregation of Alpha-Synuclein in Cells
Previous Article in Journal
Water-Soluble Fullerenol C60(OH)36 toward Effective Anti-Air Pollution Induced by Urban Particulate Matter in HaCaT Cell
Previous Article in Special Issue
Fine Tuning: Effects of Post-Translational Modification on Hsp70 Chaperones
Open AccessReview

HSP-Target of Therapeutic Agents in Sepsis Treatment

Department of Basic and Oral Biology, School of Dentistry of Ribeirão Preto, University of Sao Paulo, Ribeirão Preto, SP 14040-904, Brazil
Department of Neurosciences and Behavioral Sciences of Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, SP 14040-900, Brazil
Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP 14040-903, Brazil
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(17), 4255;
Received: 22 July 2019 / Revised: 14 August 2019 / Accepted: 15 August 2019 / Published: 30 August 2019
(This article belongs to the Special Issue Molecular Chaperones 2.0)
Sepsis is a syndrome characterized by a dysregulated inflammatory response, cellular stress, and organ injury. Sepsis is the main cause of death in intensive care units worldwide, creating need for research and new therapeutic strategies. Heat shock protein (HSP) analyses have recently been developed in the context of sepsis. HSPs have a cytoprotection role in stress conditions, signal to immune cells, and activate the inflammatory response. Hence, HSP analyses have become an important focus in sepsis research, including the investigation of HSPs targeted by therapeutic agents used in sepsis treatment. Many therapeutic agents have been tested, and their HSP modulation showed promising results. Nonetheless, the heterogeneity in experimental designs and the diversity in therapeutic agents used make it difficult to understand their efficacy in sepsis treatment. Therefore, future investigations should include the analysis of parameters related to the early and late immune response in sepsis, HSP localization (intra or extracellular), and time to the onset of treatment after sepsis. They also should consider the differences in experimental sepsis models. In this review, we present the main results of studies on therapeutic agents in targeting HSPs in sepsis treatment. We also discuss limitations and possibilities for future investigations regarding HSP modulators. View Full-Text
Keywords: chaperone; systemic inflammation; immune response; organ dysfunction; heat shock protein chaperone; systemic inflammation; immune response; organ dysfunction; heat shock protein
Show Figures

Graphical abstract

MDPI and ACS Style

Vulczak, A.; Catalão, C.H.R.; Freitas, L.A.P.; Rocha, M.J.A. HSP-Target of Therapeutic Agents in Sepsis Treatment. Int. J. Mol. Sci. 2019, 20, 4255.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop